Ian C. Kohnle
YOU?
Author Swipe
View article: 1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity Open
Background Immune checkpoint blockade is effective for a subset of patients across many cancers, but most patients are refractory to current immunotherapies and new approaches are needed to overcome resistance.1 2 The protein ty…
View article: The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity Open
View article: In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma
In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma Open
View article: Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade Open